Yu Bo, Zhang Yalong, Wang Tianyu, Guo Jiayu, Kong Chenyang, Chen Zhongbao, Ma Xiaoxiong, Qiu Tao
Department of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, People's Republic of China.
J Inflamm Res. 2023 Mar 27;16:1405-1418. doi: 10.2147/JIR.S396604. eCollection 2023.
The mitogen-activated protein kinase signaling pathway can be activated by a variety of growth factors, cytokines, and hormones, and mediates numerous intracellular signals related to cellular activities, including cell proliferation, motility, and differentiation. It has been widely studied in the occurrence and development of inflammation and tumor. Hepatic ischemia-reperfusion injury (HIRI) is a common pathophysiological phenomenon that occurs in surgical procedures such as lobectomy and liver transplantation, which is characterized by severe inflammatory reaction after ischemia and reperfusion. In this review, we mainly discuss the role of p38, ERK1/2, JNK in MAPK family and TAK1 and ASK1 in MAPKKK family in HIRI, and try to find an effective treatment for HIRI.
丝裂原活化蛋白激酶信号通路可被多种生长因子、细胞因子和激素激活，并介导与细胞活动相关的众多细胞内信号，包括细胞增殖、运动和分化。它在炎症和肿瘤的发生发展中已得到广泛研究。肝缺血再灌注损伤（HIRI）是一种常见的病理生理现象，发生于肝叶切除术和肝移植等外科手术中，其特征是缺血和再灌注后出现严重的炎症反应。在本综述中，我们主要讨论丝裂原活化蛋白激酶（MAPK）家族中的p38、细胞外信号调节激酶1/2（ERK1/2）、应激活化蛋白激酶（JNK）以及丝裂原活化蛋白激酶激酶激酶（MAPKKK）家族中的转化生长因子β激活激酶1（TAK1）和凋亡信号调节激酶1（ASK1）在HIRI中的作用，并试图找到一种有效的HIRI治疗方法。
